Mantle Cell Lymphoma Clinical Trial
Official title:
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients
This is an open label, multicenter, fixed dose and dose escalation, phase I/II study.
The study will be conducted in 3 steps. The first one (step A) will be to ensure the safety
of the combination of Obinutuzumab (GA101) and Ibrutinib at fixed doses in patients with
relapsed or refractory Mantle Cell Lymphoma (MCL).
A total of 9 patients have been included in the first step with grouped inclusions of three
patients (safety evaluation performed at each inclusion of 3 patients).
No unacceptable toxicity has been observed during step A, thefore the second step (step B)
was initiated. The aim of the second step was to determine the MTD of the GDC-0199
(400-600-800mg/d) in combination of GA101 and Ibrutinib (both respecting the previous doses)
by using a Continual Reassessment Method. This dose escalation method was used until the 12th
patient (3 patients included at 400mg/d of GDC-0199-(no DLT), 3 at 600mg/d- (no DLT) and 6 at
800mg/d, (not DLT reported so far). Once the last patient of the 800mg cohort is evaluated
for DLT, all other patients will be treated at the dose of 400mg/d of GDC-0199.
The third step (step C) for untreated patients will be conducted at the dose of 400mg/d of
GDC-0199. The aim of step C is to confirm the safety profile of the GA101 + Ibrutininb +
GDC-199 combination according to step B result. 15 patients will be included in this step.
The study will be conducted into 3 steps for respecting the optimal safety of the OASIS
trial:
Step A :
The primary objective of step A is to evaluate the safety of the combination of GA101 +
Ibrutinib at fixed doses (560 mg per day of Ibrutinib + 1000 mg of GA101), in patients with
relapsed or refractory Mantle Cell Lymphoma (MCL).
Secondary objectives:
- To describe the efficacy of the combination of GA101 and Ibrutinib in terms of clinical
benefits response (overall response rate, complete response rate, partial response rate
Cheson 99 and 07 criteria and Working Group Revised Response Criteria for Malignant
Lymphomas 14), overall survival, progression free survival.
- To describe the safety and tolerability of the combination of GA101 and Ibrutinib
- To establish a bio-bank to explore biomarkers and mechanisms of action including
resistance
Step B : Step B started because no unacceptable toxicity occurred in patients included in the
step A.
The primary objective of this step is to determine the maximal tolerated dose (MTD) of the
GDC-0199 in addition to the GA101 and Ibrutinib in relapsed refractory MCL patients by using
a Continual Reassessment Method (CRM), used up to the 12th enrolled patients. No DLT occured
for the first 12 patients. Based on the most recent publications, the dose of 400mg/d will be
used from the 13th to the 24th patients (no CRM used).
Secondary objectives:
- To describe the efficacy of the combination GA101, Ibrutinib and GDC-0199 in terms of
clinical benefits response (overall response rate, complete response rate, partial
response rate Cheson 99 and 07 criteria and Working Group Revised Response Criteria for
Malignant Lymphomas 14), overall survival, progression-free survival.
- To describe the safety and tolerability of the novel combination of GDC-0199, GA101 and
Ibrutinib
- To establish a bio-bank to explore biomarkers and mechanism of action including
resistance
Step C :
This step has started because no unacceptable toxicity was observed during the second step.
The primary objective of this step is to confirm the safety of the combination of GA101 +
Ibrutinib + GDC-199 at fixed doses (560 mg per day of Ibrutinib + 1000 mg of GA101, 400mg/d
of GDC-199 ), in patients with untreated Mantle Cell Lymphoma (MCL), at end of Cycle 2.
Secondary objectives :
- To describe the efficacy of the combination GA101, Ibrutinib and GDC-0199 in terms of
clinical benefits response (overall response rate, complete response rate, partial
response rate cheson 99 and 07 criteria and Working Group Revised Response Criteria for
Malignant Lymphomas 14), overall survival, progression-free survival.
- To describe the safety and tolerability of the novel combination of GDC-0199, GA101 and
Ibrutinib
- To establish a bio-bank to explore biomarkers and mechanism of action including
resistance
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Recruiting |
NCT05976763 -
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
|
Phase 3 | |
| Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05471843 -
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076097 -
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03891355 -
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL
|
Phase 2 | |
| Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
| Terminated |
NCT03585725 -
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
|
Early Phase 1 | |
| Recruiting |
NCT02892695 -
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
| Completed |
NCT01665768 -
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
|
Phase 2 | |
| Completed |
NCT01437709 -
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00963534 -
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
|
Phase 1/Phase 2 | |
| Completed |
NCT00921414 -
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
|
Phase 3 | |
| Withdrawn |
NCT00541424 -
Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma
|
N/A | |
| Completed |
NCT01456351 -
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
|
Phase 3 | |
| Completed |
NCT01851551 -
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT03295240 -
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
|
Early Phase 1 |